An ink composition including at least one curable monomer; at least one gellant; an optional photoinitiator; and an optional colorant; wherein the ink composition has a viscosity of less than 10.sup.6 centipoise at a temperature of from about 20 C. to about 40 C.; and wherein the ink composition has the characteristics of being both ink jettable and pinnable at a temperature of from about 20 C. to about 40 C.

An ink composition including at least one curable monomer; at least one gellant; an optional photoinitiator; and an optional colorant; wherein the ink composition has a viscosity of less than 10.sup.6 centipoise at a temperature of from about 20 C. to about 40 C.; and wherein the ink composition has the characteristics of being both ink jettable and pinnable at a temperature of from about 20 C. to about 40 C.

The present invention relates to radiolabelled compounds for in vivo imaging or treatment of diseases or conditions characterized by expression of prostate-specific membrane antigen.

The present invention relates to radiolabelled compounds for in vivo imaging or treatment of diseases or conditions characterized by expression of prostate-specific membrane antigen.

Disclosed are a novel piperlongumine-based compound, an immuno regulator containing as an active ingredient the compound, or a pharmaceutically acceptable salt or solvate thereof, and a health functional food for immune regulation.

Disclosed are a novel piperlongumine-based compound, an immuno regulator containing as an active ingredient the compound, or a pharmaceutically acceptable salt or solvate thereof, and a health functional food for immune regulation.

The present invention relates to a sacubitril intermediate and a preparation method thereof. The sacubitril intermediate disclosed herein can be prepared by a deprotection reaction of a compound. In addition, the intermediate can be used as a raw material to synthesize sacubitril.

The present invention relates to a sacubitril intermediate and a preparation method thereof. The sacubitril intermediate disclosed herein can be prepared by a deprotection reaction of a compound. In addition, the intermediate can be used as a raw material to synthesize sacubitril.

The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.

The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.